



FOR IMMEDIATE RELEASE

7 November 2024

Oncogenesis Advances Cervical Cancer Screening

Acquisition will accelerate commercialization of world's 1st point-of-care screening test

[Salinas, CA November 7, 2024] Oncogenesis (www.oncogenx.com) announces that it has acquired the exclusive rights to the intellectual property of Proof Dx's point of care CRISPR-based diagnostics system for utilization of Oncogenesis' proprietary biomolecular assay. This transaction will accelerate OncoGenesis' deployment of its assay-based cervical cancer and pre-cancer detection system known as CerMark®, moving screening beyond sample triaging via HPV alone.

The Proof platform will allow OncoGenesis to initially deploy the system to medical office-based laboratories and mobile clinics, removing the need for large-scale laboratory infrastructure to analyze patients' samples for high-risk HPV AND cervical disease. The Proof platform consists of a disposable, single-use cartridge and a bench-top analyzer which can yield results in under 30 mins, enabling single visit screening for treatable disease.

"Cervical cancer is the fourth leading cause of death among women and hence, once available, CerMark will expand access to screening for those eligible where single-visit screening and treatment are necessary," stated Jovelle Fernandez, MD, PhD, CEO and President of Oncogenesis, and gynecologic oncologist.

Combined with OncoGenesis' iPap®, CerMark will allow for complete and rapid screening and detection of treatable lesions and disease at the point of care, and at lower cost than current methods, enabling expansion of screening to the millions of women who today do not have access to it.

The iPap is the world's first, patented device that allows a woman to self-collect her own cervical cell sample necessary to identify treatable cancer and pre-cancer, something HPV testing of vaginal samples alone cannot accomplish.

Access to screening, while improving due to self-sampling and HPV testing, is still impeded by the need for complex HPV testing and multiple physician visits to commence treatment. This is one of the major factors why cervical cancer continues to affect women with an estimated 660,000 diagnosed worldwide in 2022. Dr. Fernandez continued, "Imagine a situation where you do not need to wait for days or weeks for the results, and without the unnecessary discomfort of specimen collection, you would know whether you have cervical cancer or pre-cancer in minutes and can commence treatment immediately with your physician. This fits the 'see and treat' paradigm necessary in most parts of the world."

About OncoGenesis, Inc.:

OncoGenesis is on a mission to help eliminate cervical cancer with early detection of HPV and cervical disease using effective, fast, accessible and affordable platform thereby enabling prompt treatment.

For inquiries or more information, please contact:

Media Inquiries: Media@Oncogenx.com

Investor Relations: InvestorRelations@Oncogenx.com